Evidence map›Paper›PMID 31050187›Full record

ArticlePediatric blood & cancer2019

Severe therapy-related toxicities after treatment for Hodgkin lymphoma due to a pathogenic TERT variant and shortened telomeres.

Jennifer E Agrusa, Alison A Bertuch, Courtney D DiNardo, Sharon E Plon, Olive S Eckstein

Open access · greenAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric blood & cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Pathogenic Loss-of-Function GermlineJCO precision oncology · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jennifer E AgrusaDepartment of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-8932-863X
Alison A BertuchDepartment of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sharon E PlonDepartment of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.
Olive S EcksteinDepartment of Pediatrics, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, Texas.ORCID 0000-0002-1895-8810
Baylor College of Medicine · USThe University of Texas MD Anderson Cancer Center · US

Funding

PEDIATRIC ONCOLOGY CLINICAL RESEARCH TRAINING PROGRAMK12CA090433 · NCI · BAYLOR COLLEGE OF MEDICINE · PI CARL E ALLEN, Donald W. Parsons · 2002 to 2026
$18.5M
Molecular Genetics of the Telomere Biology DisordersR01HL131744 · NHLBI · BAYLOR COLLEGE OF MEDICINE · PI BERTUCH, ALISON A, HOCKEMEYER, DIRK · 2016 to 2025
$4.5M
NCATS NIH HHS L40 TR001681NCI NIH HHS K12 CA090433NHLBI NIH HHS R01 HL131744NIH HHS 2K12CA090433-16NIH HHS SPORE P50 CA10063
6 · The paper itself

Abstract

Telomere biology disorders predispose affected individuals to specific malignancies and organ fibrosis in tissues sensitive to telomere length (TL) shortening, especially after exposure to chemotherapy and radiation. We report a case of a 17-year-old female with Hodgkin lymphoma who developed severe chemotherapy-related toxicities. She was subsequently found to have peripheral blood lymphocyte TL < 1st percentile and a pathogenic variant in TERT inherited from her father. This case demonstrates that early genetic evaluation of patients who experience greater than expected therapy-related toxicities may be warranted to help guide further decisions regarding therapy, imaging modalities, and lifelong cancer prevention surveillance.

Indexed as

MutationAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsFemaleHodgkin DiseaseHumansMaleNeutropeniaPeripheral Nervous System DiseasesPrognosisSeverity of Illness IndexTelomeraseTelomere ShorteningTelomeraseTERT protein, humanHodgkin diseaselate effects of cancer treatmentlymphomaMDSmolecular geneticstelomerase

Identifiers

PMID31050187
PMCPMC7880543
OpenAlexW2943587344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.